Anti-PAD4 antibodies link autoimmunity to PAD4 with CTL-associated rheumatoid arthritis
Annals of the Rheumatic Diseases · 2026-08 · 85 (8) · 1507-1519
DOI: 10.1016/j.ard.2026.04.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of the Rheumatic Diseases, 2026-08. Verfasst von Kusuma Ananth und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, T-Lymphocytes, Cytotoxic, Autoantibodies, Autoimmunity. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIAMS NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
OBJECTIVES: We aimed to study the serologic, genetic, and immunologic underpinnings associated with cytotoxic T lymphocytes (CTLs) in rheumatoid arthritis (RA), using T-large granular lymphocytic leukaemia with comorbid RA (T-LGLL/RA) as a model of CTL-linked RA. METHODS: We used blood samples and paired clinical data from patients with RA, T-LGLL/RA, T-LGLL and healthy controls. Serological characterisation was performed using anti-cyclic citrullinated peptide 3.1 (anti-CCP3.1) enzyme-linked immunosorbent assay, multiplex RA autoantigen array, and radiolabelled peptidylarginine deiminase type III and IV (PAD4) immunoprecipitations. Genetic characterisation was performed using PADI4 single nucleotide polymorphism TaqMan genotyping assays and droplet digital polymerase chain reaction for signal transducer and activator of transcription 3 (STAT3) mutations. Multiparameter flow cytometry and pentamer binding assays were performed to immunophenotype CTLs and characterise PAD4-specific CTLs, respectively. RESULTS: Patients with T-LGLL/RA had enhanced anticitrullinated protein antibody responses compared with RA, and a strikingly higher frequency of anti-PAD4 antibodies (60% vs 27%, P < .0001). Among patients with T-LGLL, PADI4 single nucleotide polymorphisms were associated with anti-PAD4-positive RA (20% vs 3%, P = .02), and anti-PAD4 antibody levels were inversely correlated with absolute neutrophil count (Spearman's rho = -0.236; P = .02). Activating STAT3 mutations were associated with anti-PAD4 antibodies in both T-LGLL/RA (90% vs 74%, P = .047) and RA (39% vs 9%, P = .002). Flow cytometric characterisation of CTLs showed that anti-PAD4-positive RA was enriched for CD57+, CD7 low, T effector memory cells re-expressing CD45RA (TEMRA) CTLs. Furthermore, PAD4-specific CTLs were detected in anti-PAD4+ patients with RA and expressed elevated levels of CD69, CD57, and KLRG1, and a TEMRA phenotype. CONCLUSIONS: These data demonstrate a mechanistic link between autoimmunity to PAD4 and CTL-associated disease in RA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
- Division of Hematology/Oncology, Department of Medicine, University of Virginia School of Medicine, Charlottesville, VA, USA.
- Division of Immunology and Rheumatology, Stanford School of Medicine, Stanford, CA, USA; The Geriatric Research, Education, and Clinical Center, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA.
- Division of Rheumatology & Immunology, Department of Medicine, University of Virginia School of Medicine, Charlottesville, VA, USA.
- Division of Hematology/Oncology, Department of Medicine, University of Virginia School of Medicine, Charlottesville, VA, USA. Electronic address: tl7cs@uvahealth.org.
- Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: edarrah1@jhmi.edu.
Förderung
- NCI NIH HHS
- NIAMS NIH HHS
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- National Cancer Institute
- National Institute of Allergy and Infectious Diseases
- Patient-Centered Outcomes Research Institute
Zitieren
APA
Ananth, K., Moosic, K. B., Gomez-Banuelos, E., Wang, H., Trejo-Zambrano, I., Johnson, R., Kirschmann, J. M., Deddens, T., Elghawy, O., Shemo, B., Robinson, W. H., Kimpel, D., Bingham, C. O., Feith, D. J., Antiochos, B., Andrade, F., Loughran, T. P., & Darrah, E. (2026). Anti-PAD4 antibodies link autoimmunity to PAD4 with CTL-associated rheumatoid arthritis. Annals of the Rheumatic Diseases, 85(8), 1507-1519. https://doi.org/10.1016/j.ard.2026.04.006
Vancouver
Ananth K, Moosic KB, Gomez-Banuelos E, Wang H, Trejo-Zambrano I, Johnson R, et al. Anti-PAD4 antibodies link autoimmunity to PAD4 with CTL-associated rheumatoid arthritis. Annals of the Rheumatic Diseases. 2026;85(8):1507-1519. doi:10.1016/j.ard.2026.04.006
BibTeX
@article{Ananth2026,
author = {Ananth, Kusuma and Moosic, Katharine B and Gomez-Banuelos, Eduardo and Wang, Hong and Trejo-Zambrano, Isabel and Johnson, Ramona and Kirschmann, Jessica Marie and Deddens, Tess and Elghawy, Omar and Shemo, Bryna and Robinson, William H and Kimpel, Donald and Bingham, Clifton O and Feith, David J and Antiochos, Brendan and Andrade, Felipe and Loughran, Thomas P and Darrah, Erika},
title = {Anti-PAD4 antibodies link autoimmunity to PAD4 with CTL-associated rheumatoid arthritis},
journal = {Annals of the Rheumatic Diseases},
year = {2026},
volume = {85},
number = {8},
pages = {1507--1519},
doi = {10.1016/j.ard.2026.04.006}
}
EUVIMED